Lars D. Engstrom

4.3k total citations
22 papers, 434 citations indexed

About

Lars D. Engstrom is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Lars D. Engstrom has authored 22 papers receiving a total of 434 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 8 papers in Oncology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lars D. Engstrom's work include Cancer-related gene regulation (8 papers), Colorectal Cancer Treatments and Studies (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Lars D. Engstrom is often cited by papers focused on Cancer-related gene regulation (8 papers), Colorectal Cancer Treatments and Studies (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Lars D. Engstrom collaborates with scholars based in United States. Lars D. Engstrom's co-authors include James G. Christensen, Ruth Aranda, Peter Olson, David M. Briere, Jill Hallin, Niranjan Sudhakar, Daniel S. Wechsler, Andressa L. Sodré, David Woods and Jeffrey S. Weber and has published in prestigious journals such as Cancer Research, Molecular Cancer Therapeutics and Bioorganic & Medicinal Chemistry.

In The Last Decade

Lars D. Engstrom

19 papers receiving 429 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lars D. Engstrom United States	9	281	204	80	74	48	22	434
Victoria L. Peek United States	6	126 0.4×	157 0.8×	71 0.9×	53 0.7×	45 0.9×	20	312
Agnes Csiszar Austria	8	205 0.7×	227 1.1×	108 1.4×	44 0.6×	92 1.9×	12	428
Bruno Fang United States	11	231 0.8×	189 0.9×	64 0.8×	148 2.0×	47 1.0×	33	458
Tao Osgood United States	6	158 0.6×	185 0.9×	27 0.3×	58 0.8×	43 0.9×	14	308
Zhongping Tang China	10	331 1.2×	167 0.8×	104 1.3×	73 1.0×	135 2.8×	12	494
Jingquan Jia United States	10	116 0.4×	114 0.6×	51 0.6×	58 0.8×	37 0.8×	28	246
Anja Hohmeyer Germany	3	234 0.8×	122 0.6×	91 1.1×	33 0.4×	79 1.6×	3	390
Kevin S. Quackenbush United States	12	228 0.8×	219 1.1×	30 0.4×	71 1.0×	112 2.3×	17	423
Ben Staal United States	9	219 0.8×	140 0.7×	39 0.5×	62 0.8×	61 1.3×	14	365

Countries citing papers authored by Lars D. Engstrom

Since Specialization

Citations

This map shows the geographic impact of Lars D. Engstrom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars D. Engstrom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars D. Engstrom more than expected).

Fields of papers citing papers by Lars D. Engstrom

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lars D. Engstrom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars D. Engstrom. The network helps show where Lars D. Engstrom may publish in the future.

Co-authorship network of co-authors of Lars D. Engstrom

This figure shows the co-authorship network connecting the top 25 collaborators of Lars D. Engstrom. A scholar is included among the top collaborators of Lars D. Engstrom based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lars D. Engstrom. Lars D. Engstrom is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Negrão, Marcelo V., David Molkentine, Laura D. Hover, et al.. (2024). Abstract 1212: Impact of KEAP1/STK11 co-mutations and NRF2 signaling on resistance to adagrasib in advanced NSCLC. Cancer Research. 84(6_Supplement). 1212–1212.

Waters, Laura, Ruth Aranda, Krystal Moya, et al.. (2024). Abstract 3319: The MTA-cooperative PRMT5 inhibitor, MRTX1719, demonstrates increased anti-tumor activity in combination with KRAS mutant-selective inhibitors in MTAP del,KRAS-mutant cancers. Cancer Research. 84(6_Supplement). 3319–3319. 2 indexed citations

Edwards, A. Cole, Clint A. Stalnecker, Jill Hallin, et al.. (2023). Abstract B009: TEAD inhibition overcomes YAP1/TAZ-driven resistance to RAS inhibitors in KRASG12C-mutant cancers. Molecular Cancer Research. 21(5_Supplement). B009–B009.

Sudhakar, Niranjan, Jade Laguer, David M. Briere, et al.. (2023). Abstract 3499: Inhibition of SOS1 by MRTX0902 augments the anti-tumor response of the targeted EGFR inhibitor osimertinib in NSCLC. Cancer Research. 83(7_Supplement). 3499–3499.

Waters, Laura, Ruth Aranda, Krystal Moya, et al.. (2023). Abstract 2779: Identification of mechanism-based combination targets effective with the MTA-cooperative PRMT5 inhibitor MRTX1719 for the treatment of MTAP deleted cancers. Cancer Research. 83(7_Supplement). 2779–2779. 1 indexed citations

Aranda, Ruth, Laura Waters, Krystal Moya, et al.. (2023). Abstract 2778: A novel MTA-cooperative PRMT5 inhibitor, MRTX1719, stabilizes the ternary MTA-PRMT5 complex and leads to synthetic lethality in MTAP deleted cancers. Cancer Research. 83(7_Supplement). 2778–2778. 1 indexed citations

Smith, Christopher R., Ruth Aranda, James G. Christensen, et al.. (2022). Design and evaluation of achiral, non-atropisomeric 4-(aminomethyl)phthalazin-1(2H)-one derivatives as novel PRMT5/MTA inhibitors. Bioorganic & Medicinal Chemistry. 71. 116947–116947. 8 indexed citations

Briere, David M., Shuai Li, Andrew Calinisan, et al.. (2021). The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy. Molecular Cancer Therapeutics. 20(6). 975–985. 109 indexed citations

Smith, Christopher R., Svitlana Kulyk, Lars D. Engstrom, et al.. (2021). Abstract LB003: Fragment based discovery of MRTX9768, a synthetic lethal-based inhibitor designed to bind the PRMT5-MTA complex and selectively target MTAP/CDKN2A-deleted tumors. Cancer Research. 81(13_Supplement). LB003–LB003. 10 indexed citations

10.

Smith, Christopher R., Lars D. Engstrom, Svitlana Kulyk, et al.. (2021). Abstract P165: MRTX1719: A first-in-class MTA-cooperative PRMT5 inhibitor that selectively elicits antitumor activity in MTAP/CDKN2A deleted cancer models. Molecular Cancer Therapeutics. 20(12_Supplement). P165–P165. 2 indexed citations

11.

Hansen, Ryan J., Steven V. Horton, E. Lorena Mora‐Blanco, et al.. (2021). Abstract LBA005: Detection of KRAS amplification on extrachromosomal DNA (ecDNA) upon acquired resistance to KRASG12C inhibitors. Molecular Cancer Therapeutics. 20(12_Supplement). LBA005–LBA005. 1 indexed citations

12.

Engstrom, Lars D., Laura Waters, Sole Gatto, et al.. (2020). Abstract 5684: Drug-anchored in vitro and in vivo CRISPR screens to identify targetable vulnerabilities and modifiers of response to MRTX849 in KRASG12C-mutant models. Cancer Research. 80(16_Supplement). 5684–5684. 1 indexed citations

13.

Hallin, Jill, Andrew Calinisan, Lauren Hargis, et al.. (2020). Abstract LB-098: The anti-tumor activity of the KRAS G12C inhibitor MRTX849 is augmented by cetuximab in CRC tumor models. Cancer Research. 80(16_Supplement). LB–98. 1 indexed citations

14.

Christensen, James G., Jay B. Fell, Jill Hallin, et al.. (2019). Abstract C069: The identification of MRTX849, a novel KRASG12C inhibitor under clinical investigation, provides insight toward therapeutic susceptibility of KRAS mutant cancers. Molecular Cancer Therapeutics. 18(12_Supplement). C069–C069. 5 indexed citations

15.

Briere, David M., Andrew Calinisan, Ruth Aranda, et al.. (2019). Abstract LB-C09: The KRASG12C inhibitor MRTX849 reconditions the tumor immune microenvironment and leads to durable complete responses in combination with anti-PD-1 therapy in a syngeneic mouse model. Molecular Cancer Therapeutics. 18(12_Supplement). LB–C09. 10 indexed citations

16.

Briere, David M., Niranjan Sudhakar, David Woods, et al.. (2017). The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy. Cancer Immunology Immunotherapy. 67(3). 381–392. 117 indexed citations

17.

Zou, Helen Y., Qiuhua Li, Joseph H. Lee, et al.. (2012). Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor. Molecular Cancer Therapeutics. 11(4). 1036–1047. 57 indexed citations

18.

Engstrom, Lars D., Andrew Youkilis, Datong Zheng, et al.. (2004). MXI1-0, an Alternatively Transcribed Mxi1 Isoform, Is Overexpressed in Glioblastomas. Neoplasia. 6(5). 660–673. 18 indexed citations

19.

Wechsler, Daniel S., Lars D. Engstrom, Brian M. Alexander, David G. Motto, & Diane Roulston. (2002). A novel chromosomal inversion at 11q23 in infant acute myeloid leukemia fuses MLL to CALM, a gene that encodes a clathrin assembly protein. Genes Chromosomes and Cancer. 36(1). 26–36. 33 indexed citations

20.

Taj, Mary, Lars D. Engstrom, Zhi Zeng, et al.. (2001). Mxi1, a Myc antagonist, suppresses proliferation of DU145 human prostate cells. The Prostate. 47(3). 194–204. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact